Linked Life Data

19318490

Source:http://linkedlifedata.com/resource/pubmed/id/19318490

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2009-4-2
pubmed:abstractText
Gefitinib targeting of the epidermal growth factor receptor (EGFR) has shown limited activity in clinical trials of head and neck squamous cell carcinoma (HNSCC). To investigate the underlying molecular mechanism, the proteomic signatures and responses of EGFR and downstream signals have been studied in a panel of HNSCC cell lines and tumor specimens pre- and post-gefitinib treatment.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2361-72
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:19318490-Antineoplastic Agents, pubmed-meshheading:19318490-Blotting, Western, pubmed-meshheading:19318490-Carcinoma, Squamous Cell, pubmed-meshheading:19318490-Cell Line, Tumor, pubmed-meshheading:19318490-Cell Survival, pubmed-meshheading:19318490-Clinical Trials, Phase I as Topic, pubmed-meshheading:19318490-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:19318490-Epidermal Growth Factor, pubmed-meshheading:19318490-Head and Neck Neoplasms, pubmed-meshheading:19318490-Humans, pubmed-meshheading:19318490-Inhibitory Concentration 50, pubmed-meshheading:19318490-NF-kappa B, pubmed-meshheading:19318490-Phosphorylation, pubmed-meshheading:19318490-Protein Array Analysis, pubmed-meshheading:19318490-Protein Kinase Inhibitors, pubmed-meshheading:19318490-Proteomics, pubmed-meshheading:19318490-Quinazolines, pubmed-meshheading:19318490-Receptor, Epidermal Growth Factor, pubmed-meshheading:19318490-Signal Transduction, pubmed-meshheading:19318490-Tumor Markers, Biological
pubmed:year
2009
pubmed:articleTitle
Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
pubmed:affiliation
Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural